Barcelona, Catalonia, Spain Capital Cell appeared to be the VC, which was created in 2014. The company was established in Europe in Spain. The main department of described VC is located in the Barcelona.
This organization was formed by Daniel Oliver. The overall number of key employees were 4.
The typical case for the fund is to invest in rounds with 1-2 participants. Despite the Capital Cell, startups are often financed by EASME - EU Executive Agency for SMEs, Inveready Technology Investment Group, Calculus Capital. The meaningful sponsors for the fund in investment in the same round are Ship2B, Inveready Technology Investment Group, ENISA. In the next rounds fund is usually obtained by EASME - EU Executive Agency for SMEs, Ship2B, Inveready Technology Investment Group.
The fund has specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Medical Device, Life Science. Among the most popular portfolio startups of the fund, we may highlight Bionure, Ability Pharmaceuticals, Arcis Biotechnology. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Spain.
The common things for fund are deals in the range of 100 thousands - 1 million dollars. The average startup value when the investment from Capital Cell is 5-10 millions dollars. The fund is constantly included in 2-6 investment rounds annually. Considering the real fund results, this VC is 5 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2017.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Allgeier SE | - |
| BPI Capital Partners | New York, New York, United States |
| Caton Technology (Asia) | China, Hong Kong, Hong Kong Island |
| Chuanghehui Fund | China, Shanghai, Shanghai |
| Creditreform AG | Germany, Neuss, North Rhine-Westphalia |
| Fuyu (Shanghai) Investment Management | - |
| Indian Institute of Technology, Ropar | - |
| Intesa Sanpaolo | Italy, Piemonte, Torino |
| Lang Sheng Investment | China, Shanghai |
| Lingxian Ziben | - |
| Matmut | France, Haute-Normandie, Rouen |
| Open Philanthropy Project | California, San Francisco, United States |
| Probiocon | - |
| University of Cincinnati | Cincinnati, Ohio, United States |
| V13 Invest | - |
| Wood Creek Capital Management | Connecticut, New Haven, United States |
| Zenmen | China, Shanghai |
| Zhanrui Xinfu Equity Investment Fund Management | China, Shanghai |
| Zhongfu Capital | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Exheus | $767K | 29 Nov 2022 | Barcelona, Catalonia, Spain | ||
Inrobics | $413K | 02 Aug 2022 | Madrid, Madrid, Spain | ||
MoWoot | $1M | 17 Mar 2022 | Barcelona, Catalonia, Spain | ||
Kintsugi Therapeutics | $1M | 12 Nov 2021 | Barcelona, Catalonia, Spain | ||
Aortyx | $1M | 08 Apr 2021 | Barcelona, Catalonia, Spain | ||
| $722K | 31 Mar 2020 | Barcelona, Catalonia, Spain | |||
Laminar Pharma | $2M | 01 Sep 2019 | Palma, Balearic Islands, Spain | ||
RheoDx | $413K | 02 Apr 2019 | Barcelona, Catalonia, Spain | ||
Ducentis BioTherapeutics | $1M | 01 Aug 2017 | England |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Exheus | $767K | 29 Nov 2022 | Barcelona, Catalonia, Spain | ||
Inrobics | $413K | 02 Aug 2022 | Madrid, Madrid, Spain | ||
MoWoot | $1M | 17 Mar 2022 | Barcelona, Catalonia, Spain | ||
Kintsugi Therapeutics | $1M | 12 Nov 2021 | Barcelona, Catalonia, Spain | ||
Aortyx | $1M | 08 Apr 2021 | Barcelona, Catalonia, Spain | ||
| $722K | 31 Mar 2020 | Barcelona, Catalonia, Spain | |||
Laminar Pharma | $2M | 01 Sep 2019 | Palma, Balearic Islands, Spain | ||
RheoDx | $413K | 02 Apr 2019 | Barcelona, Catalonia, Spain | ||
Ducentis BioTherapeutics | $1M | 01 Aug 2017 | England |
